Creating new value and providing information through digital technologies
First written in FY2020. 8 of 13 entries say "Restated". Latest entry: FY2025.
32 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「In addition, across the Group, we will pursue corporate transformation through digital technologies and IT, build and maintain a secure IT infrastructure capable of supporting globalization and change, and promote digital transformation, including transformation of the drug discovery value chain.」
The policy of building and maintaining a secure global IT infrastructure and pursuing company-wide digital transformation, including the drug discovery value chain, has been reaffirmed. - FY2024RestatedAnnual report
「In addition, across the Group, we will pursue corporate transformation through digital technologies and IT, renew our IT infrastructure with a simply structured architecture in preparation for globalization, and promote digital transformation, including transformation of the drug discovery value chain.」
The policy of advancing company-wide digital transformation, renewing the global IT infrastructure and transforming the drug discovery value chain has been reaffirmed. - FY2024-Q1RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased by ¥1,800 million, or 8.1%, year on year to ¥23,500 million, due to increases in co-promotion fees accompanying higher sales of Forxiga Tablets and expenses related to strengthening the IT- and digital-related information infrastructure.」
Continued investment in strengthening the IT- and digital-related information infrastructure, and the resulting increase in related expenses, were cited as a factor behind the increase in first-quarter selling, general and administrative expenses. - FY2023ReframedAnnual report
「In addition, across the Group, we will pursue corporate transformation through digital technologies and IT, renew our IT infrastructure with a simply structured architecture in preparation for globalization, and promote digital transformation, including transformation of the drug discovery value chain.」
The scope of digital initiatives has expanded from using digital technologies mainly for web-based meetings and remote lectures to company-wide digital transformation, including renewal of the global IT infrastructure and transformation of the drug discovery value chain. - FY2023-Q3RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased by ¥8,700 million, or 15.1%, year on year to ¥66,100 million, due to increases in co-promotion fees accompanying higher sales of Forxiga Tablets and expenses related to strengthening the IT- and digital-related information infrastructure.」
Continued investment in strengthening the IT- and digital-related information infrastructure, and the resulting increase in related expenses, were cited as factors behind cumulative third-quarter selling, general and administrative expenses. - FY2023-Q2RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased by ¥5,300 million, or 14.0%, year on year to ¥42,900 million, due to increases in co-promotion fees accompanying higher sales of Forxiga Tablets and expenses related to strengthening the IT- and digital-related information infrastructure.」
Continued investment in strengthening the IT- and digital-related information infrastructure, and the resulting increase in related expenses, were cited as factors behind cumulative second-quarter selling, general and administrative expenses. - FY2023-Q1RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased by ¥2,800 million, or 14.6%, year on year to ¥21,700 million, due to increases in co-promotion fees accompanying higher sales of Forxiga Tablets and expenses related to strengthening the IT- and digital-related information infrastructure.」
Continued investment in strengthening the IT- and digital-related information infrastructure, and the resulting increase in related expenses, were cited as factors behind first-quarter selling, general and administrative expenses. - FY2022ReframedAnnual report
「In addition, across the Group, we will pursue corporate transformation through digital technologies and IT, renew our IT infrastructure with a simply structured architecture in preparation for globalization, and promote digital transformation, including transformation of the drug discovery value chain.」
The scope of digital initiatives has expanded from information provision centered on web-based meetings and remote lectures to renewing the global IT infrastructure, transforming the drug discovery value chain and pursuing company-wide digital transformation. - FY2022-Q3RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased as operating activity expenses rose due to actively holding web-based lectures, despite activity restrictions such as MR visits to medical institutions being curtailed because of the impact of COVID-19.」
While restrictions on visits to medical institutions continue, sales and information-provision activities using web-based lectures are continuing. - FY2022-Q1RestatedAnnual report
「Selling, general and administrative expenses excluding research and development expenses increased as operating activity expenses rose due to actively holding web-based lectures, despite activity restrictions such as MR visits to medical institutions being curtailed because of the impact of COVID-19.」
While restrictions on visits to medical institutions remain, web-based lectures continue to be used actively as a sales activity. - FY2021AdvancedAnnual report
「Expenses increased for actively holding web-based lectures, expanding content on our corporate website and using new sales platforms. In addition, expenses related to the launch of new products and the addition of indications increased, as did co-promotion fees accompanying higher sales of Forxiga Tablets. As a result, expenses increased by ¥1,600 million, or 2.3%, year on year to ¥69,200 million.」
Web-based lectures, expanded content on the corporate website and the use of new sales platforms have been implemented as specific full-year sales activities. - FY2021-Q1AdvancedAnnual report
「In our sales activities, we are gradually resuming operations, starting with regions and medical institutions less affected, while pursuing the information-provision activities that are an MR's responsibility using new methods, including web-based meetings and planning remote lectures in addition to conventional visits.」
Web-based meetings and remote lectures have been introduced into sales activities as specific means of using digital technologies to provide value and information. - FY2020First statedAnnual report
「In the pharmaceutical industry, new value is being created through more active open innovation and collaboration with companies in other industries centered on digital technologies.」
Creating value through collaboration with companies in other industries centered on digital technologies has been identified for the first time as a growth opportunity, while web-based meetings and remote lectures are also described later.